160 related articles for article (PubMed ID: 21535892)
1. Antigenic repertoire of Plasmodium vivax transmission-blocking vaccine candidates from the Indian subcontinent.
Prajapati SK; Joshi H; Dua VK
Malar J; 2011 May; 10():111. PubMed ID: 21535892
[TBL] [Abstract][Full Text] [Related]
2. Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan Province, China.
Feng H; Zheng L; Zhu X; Wang G; Pan Y; Li Y; Yang Y; Lin Y; Cui L; Cao Y
Parasit Vectors; 2011 Nov; 4():224. PubMed ID: 22117620
[TBL] [Abstract][Full Text] [Related]
3. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
Zakeri S; Razavi S; Djadid ND
Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
[TBL] [Abstract][Full Text] [Related]
4. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.
Tsuboi T; Kaslow DC; Gozar MM; Tachibana M; Cao YM; Torii M
Mol Med; 1998 Dec; 4(12):772-82. PubMed ID: 9990863
[TBL] [Abstract][Full Text] [Related]
5. Genetic diversity and natural selection of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax Myanmar isolates.
Lê HG; Kang JM; Jun H; Lee J; Moe M; Thái TL; Lin K; Myint MK; Yoo WG; Sohn WM; Kim TS; Na BK
Acta Trop; 2019 Oct; 198():105104. PubMed ID: 31336059
[TBL] [Abstract][Full Text] [Related]
6. Sequence polymorphisms of Plasmodium vivax ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea.
Han ET; Lee WJ; Sattabongkot J; Jang JW; Nam MH; An SS; Suh I; Lim CS
Trop Med Int Health; 2010 Sep; 15(9):1072-6. PubMed ID: 20545923
[TBL] [Abstract][Full Text] [Related]
7. Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates.
Kang JM; Ju HL; Moon SU; Cho PY; Bahk YY; Sohn WM; Park YK; Cha SH; Kim TS; Na BK
Malar J; 2013 Apr; 12():144. PubMed ID: 23631662
[TBL] [Abstract][Full Text] [Related]
8. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.
González-Cerón L; Alvarado-Delgado A; Martínez-Barnetche J; Rodríguez MH; Ovilla-Muñoz M; Pérez F; Hernandez-Avila JE; Sandoval MA; Rodríguez Mdel C; Villarreal-Treviño C
Infect Genet Evol; 2010 Jul; 10(5):645-54. PubMed ID: 20363376
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of Plasmodium vivax ookinete (sexual stage) surface proteins (Pvs25 and Pvs28) from Thailand.
Kuesap J; Suphakhonchuwong N; Rungsihirunrat K
Infect Genet Evol; 2024 Mar; 118():105558. PubMed ID: 38244749
[TBL] [Abstract][Full Text] [Related]
10. [Transmission-blocking vaccine candidate of Plasmodium vivax Pvs25 is highly conservative among Chinese isolates].
Zheng L; Xu WM; Liu YJ; Yang YM; Cao YM
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Feb; 22(1):16-9. PubMed ID: 15283259
[TBL] [Abstract][Full Text] [Related]
11. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
[TBL] [Abstract][Full Text] [Related]
12. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28.
Tsuboi T; Kaneko O; Cao YM; Tachibana M; Yoshihiro Y; Nagao T; Kanbara H; Torii M
Parasitol Int; 2004 Sep; 53(3):211-6. PubMed ID: 15468527
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium vivax ookinete surface protein (Pvs25) is highly conserved among field isolates from five different regions of the Brazilian Amazon.
Chaves LB; Perce-da-Silva DS; Totino PRR; Riccio EKP; Baptista BO; de Souza ABL; Rodrigues-da-Silva RN; Machado RLD; de Souza RM; Daniel-Ribeiro CT; Banic DM; Pratt-Riccio LR; Lima-Junior JDC
Infect Genet Evol; 2019 Sep; 73():287-294. PubMed ID: 31077839
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
Hisaeda H; Collins WE; Saul A; Stowers AW
Vaccine; 2001 Dec; 20(5-6):763-70. PubMed ID: 11738740
[TBL] [Abstract][Full Text] [Related]
15. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
[TBL] [Abstract][Full Text] [Related]
16. Transmission-blocking vaccine of vivax malaria.
Tsuboi T; Tachibana M; Kaneko O; Torii M
Parasitol Int; 2003 Mar; 52(1):1-11. PubMed ID: 12543142
[TBL] [Abstract][Full Text] [Related]
17. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
[TBL] [Abstract][Full Text] [Related]
18. Exploration of genetic diversity of Plasmodium vivax circumsporozoite protein (Pvcsp) and Plasmodium vivax sexual stage antigen (Pvs25) among North Indian isolates.
Kaur H; Sehgal R; Kumar A; Sehgal A; Bharti PK; Bansal D; Mohapatra PK; Mahanta J; Sultan AA
Malar J; 2019 Sep; 18(1):308. PubMed ID: 31492135
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
Chaurio RA; Pacheco MA; Cornejo OE; Durrego E; Stanley CE; Castillo AI; Herrera S; Escalante AA
PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004786. PubMed ID: 27347876
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
Hisaeda H; Stowers AW; Tsuboi T; Collins WE; Sattabongkot JS; Suwanabun N; Torii M; Kaslow DC
Infect Immun; 2000 Dec; 68(12):6618-23. PubMed ID: 11083773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
